【 Pharmaceutical Network Policies and Regulations 】Recently, the "Support Policy for Promoting the High Quality Development of Medical and Health Industry Cluster in Wenjiang District, Chengdu" (hereinafter referred to as "Support Policy") was officially issued.
The "Support Policy" focuses on attracting target enterprises and cultivating potential enterprises. It focuses on research and development, transformation, manufacturing and market. During the formulation process, it always adheres to the pertinence, systematicness and scientificity of the policy, focusing on the key demands of enterprises and the needs of different types of enterprises. Its content mainly involves four aspects: supporting industrial agglomeration, accelerating the transformation of innovative achievements, financial enabling industries, and encouraging excellence and strength.
Among them, in terms of supporting industrial agglomeration, the Support Policy mainly supports the introduction of new biomedical projects, gives fixed investment incentives to major land use projects, and gives excellent carrier enterprises no more than 3 years of rent subsidies and no more than 10 million yuan of decoration equipment subsidies.
In terms of innovation achievements transformation, the Support Policy mainly provides subsidies for drug and equipment research and development, including no more than 30 million yuan for innovative drug list varieties, no more than 10 million yuan for medical device single varieties, and no more than 1 million yuan for pharmaceutical equipment, animal/pet drugs, special medical health food and other projects, The newly introduced public service platform will be supported by no more than 10 million yuan.
In terms of financial empowerment industry, we will guide the capital strength of all sectors of society to complement the financial weakness of the park, encourage financial institutions to invest in park projects, recommend projects to settle in the park, etc. We will give project landing awards of no more than 1 million yuan and project tribute awards of no more than 2 million yuan to guide project settlement, and give cumulative awards of no more than 5.5 million yuan to enterprises listing.
In terms of encouraging excellence and strengthening, the reward for local economic contribution of newly introduced enterprises for five consecutive years can be extended to eight years for enterprises that pay more than 50 million yuan in taxes after five years; A subsidy of no more than 5 million yuan will be given for the overseas listing and export sales of a single product; Step by step one-time rewards will be given to individual drugs and medical devices according to the annual sales revenue; A reward of no more than 8 million yuan will be given to those who transfer mature products from outside the zone and produce and settle accounts in the zone.
It is understood that in addition to Wenjiang, Chengdu, since this year, Beijing, Guangzhou, Zhuhai and other places have also clearly issued documents to provide financial support for innovative drug research and development, and the amount of awards is more than 10 million yuan.
In Zhuhai, on April 1, the Several Measures of Zhuhai City to Promote the High Quality Development of Biomedical and Health Industries (Draft for Comments) was released, which stipulated that chemical drugs of categories 1 to 2 and biological products would be rewarded according to the achievements of each stage of research and development. A one-time reward of no more than 3 million yuan, 5 million yuan and 10 million yuan will be given respectively for the completion of Phase I, II and III clinical trials. The annual reward for new drug R&D of a single enterprise shall not exceed 20 million yuan.
On February 19, Beijing released the "Several Measures of Haidian District to Promote the High Quality Development of the Medical and Health Industry", which supports the innovative research and development of cell and gene therapy drugs and can reward no more than 50 million yuan.
The Several Policies and Measures of Guangzhou to Promote the High Quality Development of the Biomedical Industry released on January 19 in Guangzhou, Guangdong Province, proposed to support the clinical trial research of the self-developed and transformed biological products in stages. For the new drug projects newly launched in clinical phase I, II and III research, no more than 3 million yuan, 5 million yuan and 10 million yuan of funding would be given respectively. A single enterprise receives no more than 100 million yuan of clinical trial funding annually.
The "14th Five Year Plan" Bioeconomy Development Plan has listed the biomedical industry as one of the four key development areas. With the aging of the population, the upgrading of the consumption level, and the introduction of favorable policies at the national and local levels, the scale of the biomedical industry will continue to grow in the future. By 2020, the market size of China's bio pharmaceutical industry is 3.57 trillion yuan, and it is estimated that the market size of China's bio pharmaceutical industry has exceeded 4 trillion yuan.
Disclaimer: In any case, the information or opinions expressed in this document do not constitute investment advice to anyone.
